VIDEO: Elamipretide for dry AMD progresses to phase 3 studies

ByDavid S. Boyer, MD

ByAnthony DeFino

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David S. Boyer, MD, of Retina-Vitreous Associates Medical Group in Los Angeles, discusses targeting mitochondria in retinal disease treatment.

According to Boyer, mitochondria are a “very good area to attack” when treating patients with geographic atrophy in dry age-related macular degeneration, with the ReCLAIM-2 study showing a reduction in ellipsoid zone attenuation progression and improvement in low-luminance vision after treatment with subcutaneous elamipretide. Elamipretide is now progressing to phase 3 studies.

Published by:

Sources/Disclosures

Collapse

Source:

Boyer D. The role of mitochondria in the treatment of dry macular degeneration. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Boyer reports being an advisor and investigator for Stealth BioTherapeutics.

Read more about

retinal disease

dry age-related macular degeneration

mitochondria

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment